Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.

Publication ,  Journal Article
Stenerson, M; Dufendach, K; Aksentijevich, I; Brady, J; Austin, J; Reed, AM
Published in: Arthritis Rheum
December 2011

Interleukin-1 receptor antagonist (IL-1Ra) deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. We report the case of a 2-week-old male who presented with a swollen, erythematous left index finger and elevated serum markers of inflammation. He later developed cyclical fevers, diffuse pustular skin lesions, and thrombus formation. After not responding to broad-spectrum antimicrobial therapy and achieving only moderate success with systemic steroid therapy, he was ultimately treated with recombinant IL-1Ra, anakinra, and experienced significant clinical improvement. Sequencing of his IL1RN gene revealed that the patient was compound heterozygous for a known mutation (E77X) associated with IL-1Ra deficiency and a novel mutation in exon 2 of the gene (c.140delC; p.T47TfsX4). His case highlights IL-1Ra deficiency as an autoinflammatory disease that is distinct from neonatal-onset multisystem inflammatory disease but that also responds well to anakinra. Our patient is the first reported compound heterozygote for E77X and the novel mutation in exon 2 of the gene, the latter of which adds to what will surely be a growing database of pathologic mutations in IL1RN.

Duke Scholars

Published In

Arthritis Rheum

DOI

EISSN

1529-0131

Publication Date

December 2011

Volume

63

Issue

12

Start / End Page

4018 / 4022

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Mutation
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infant, Newborn
  • Humans
  • Heterozygote
  • Hereditary Autoinflammatory Diseases
  • Exons
  • Drug Therapy, Combination
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stenerson, M., Dufendach, K., Aksentijevich, I., Brady, J., Austin, J., & Reed, A. M. (2011). The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum, 63(12), 4018–4022. https://doi.org/10.1002/art.30565
Stenerson, Matthew, Kevin Dufendach, Ivona Aksentijevich, Jillian Brady, Jared Austin, and Ann M. Reed. “The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.Arthritis Rheum 63, no. 12 (December 2011): 4018–22. https://doi.org/10.1002/art.30565.
Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum. 2011 Dec;63(12):4018–22.
Stenerson, Matthew, et al. “The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.Arthritis Rheum, vol. 63, no. 12, Dec. 2011, pp. 4018–22. Pubmed, doi:10.1002/art.30565.
Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum. 2011 Dec;63(12):4018–4022.
Journal cover image

Published In

Arthritis Rheum

DOI

EISSN

1529-0131

Publication Date

December 2011

Volume

63

Issue

12

Start / End Page

4018 / 4022

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Mutation
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infant, Newborn
  • Humans
  • Heterozygote
  • Hereditary Autoinflammatory Diseases
  • Exons
  • Drug Therapy, Combination